FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia gravis (gMG). But in clinical trials there are reports of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” https://t.co/6GBwIJ4ig4

Osteoporosis Drug May Lower Osteoarthritis Risk A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. https://t.co/fWWw2t2jzR

PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/03lNpQiVYZ

"Let the young know they will never find a more interesting, more instructive book than the patient himself." – Giorgio Baglivi

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer. https://t.co/i3FMOCbyNg

If severe refractory SLE is defined as SLEDAI-2K≥10 despite steroids & immunosuppressives; Cohort of 3,744 SLE - 14% (578) had srSLE. Median SLEDAI-2K = 12, & decreased to 6 at 6m & 12m> < 25% achieved LLDAS & only 1% attained GC-free remission @ 12 mos https://t.co/7tehA27gyT https://t.co/yef4wCpqNf

• Prevalence and outcomes of a pilot definition of severe refractory systemic lup…

Emapalumab Approved for MAS in Still’s On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with https://t.co/431PQlzBsV

TNFi are relatively contraindicated in RA pts w/ #MS. Literature review suggests for pts w/ MS and RA, teriflunomide and anti-CD20 therapies are the most suitable, and Cladribine may also be considered https://t.co/gIVaJ7Kwn0 https://t.co/1ar0q2OnzB

• https://buff.ly/FE26mXw

Fibrosis in IgG4-related disease due to the overexpression of early growth response-1 (EGR-1) by Epithelial cells that facilitates tissue fibrosis https://t.co/AEaoucfT13 https://t.co/7UVQpkj3cn https://t.co/PuCjh5LQc5

• https://buff.ly/fnQ14E7
• https://buff.ly/94QmII9

NEJM images: 55-year-old man with metastatic squamous-cell lung cancer Hx& 6-wk Hx firm, painful swelling RToe1 & RDIP3 w/ ulceration. Xray showed lytic lesions due to acrometastases - rare bony metastases distal to elbow or knee, that may may mimic gout or osteomyelitis https://t.co/1Fh1Cp9dm9

Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast https://t.co/B8lFlTwj10

• Submit Podcast Question or Comment | RheumNow

Survival in #RA pts undergoing cervical spine surgery is not good! Retrospective study of 139 RA pts who underwent Cx surgery shows higher mortality risk if they are older, w low albumin levels, high-dose pred. and have subaxial subluxation. https://t.co/hKvgaas2gh https://t.co/ygtJjb4mVl

• Risk factors affecting the vital prognosis in patients with rheumatoid arthriti…

Subclinical Synovitis Among Psoriasis Patients A systematic review shows that imaging can be used to detect subclinical synovitis among patients with psoriasis and may identify individuals at risk for future psoriatic arthritis. https://t.co/2603Aax8PP https://t.co/2XDtDg1QHh

• Subclinical Synovitis Among Psoriasis Patients | RheumNow